Limits...
FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.

Park HS, Chung JW, Jae HJ, Kim YI, Son KR, Lee MJ, Park JH, Kang WJ, Yoon JH, Chung H, Lee K - Korean J Radiol (2007 May-Jun)

Bottom Line: The SUV was significantly decreased immediately after 3-BrPA administration (2.05+/-1.21) (p = 0.002, Wilcoxon signed rank test).On the one-week follow up PET scan, the FDG uptake remained significantly lower (SUV 1.41+/-0.73) than that before treatment (p = 0.002), although three out of ten animals showed a slightly increasing tendency for the FDG uptake.There was no significant correlation between the SUV or the SUV decrease rate and the tumor necrosis rate in that range.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Seoul National University College of Medicine, Institute of Radiation Medicine, Seoul National University Medical Research Center and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea.

ABSTRACT

Objective: We wanted to investigate the feasibility of using FDG-PET for evaluating the antitumor effect of intraarterial administration of a hexokinase II inhibitor, 3-bromopyruvate (3-BrPA), in a rabbit VX2 liver tumor model.

Materials and methods: VX2 carcinoma was grown in the livers of ten rabbits. Two weeks later, liver CT was performed to confirm appropriate tumor growth for the experiment. After tumor volume-matched grouping of the rabbits, transcatheter intraarterial administration of 3-BrPA was performed (1 mM and 5 mM in five animals each, respectively). FDG-PET scan was performed the day before, immediately after and a week after 3-BrPA administration. FDG uptake was semiquantified by measuring the standardized uptake value (SUV). A week after treatment, the experimental animals were sacrificed and the necrosis rates of the tumors were calculated based on the histopathology.

Results: The SUV of the VX2 tumors before treatment (3.87+/-1.51 [mean+/-SD]) was significantly higher than that of nontumorous liver parenchyma (1.72+/-0.34) (p < 0.0001, Mann-Whitney U test). The SUV was significantly decreased immediately after 3-BrPA administration (2.05+/-1.21) (p = 0.002, Wilcoxon signed rank test). On the one-week follow up PET scan, the FDG uptake remained significantly lower (SUV 1.41+/-0.73) than that before treatment (p = 0.002), although three out of ten animals showed a slightly increasing tendency for the FDG uptake. The tumor necrosis rate ranged from 50.00% to 99.90% (85.48%+/-15.87). There was no significant correlation between the SUV or the SUV decrease rate and the tumor necrosis rate in that range.

Conclusion: Even though FDG-PET cannot exactly reflect the tumor necrosis rate, FDG-PET is a useful modality for the early assessment of the antitumor effect of intraarterial administration of 3-BrPA in VX2 liver tumor.

Show MeSH

Related in: MedlinePlus

Line graph shows the chronological SUV changes of the VX2 liver tumors in each animal. Seven animals showed a gradually decreased SUV, but the other three animals showed rising tendency of FDG uptake at one week after treatment. * Tx = treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2627418&req=5

Figure 2: Line graph shows the chronological SUV changes of the VX2 liver tumors in each animal. Seven animals showed a gradually decreased SUV, but the other three animals showed rising tendency of FDG uptake at one week after treatment. * Tx = treatment.

Mentions: The SUV was significantly decreased immediately after 3-BrPA administration (before treatment: 3.87 ±1.51 [mean ±SD], immediately after treatment: 2.05 ±1.21, p = 0.002, Wilcoxon signed rank test). On the one week follow up PET scan, the FDG uptake remained significantly lower than that before treatment (1.41 ±0.73, p = 0.002), and the SUV was persistently decreased in seven rabbits, but it showed a slightly increasing tendency in three rabbits (animals 1, 2 and 6) (Fig. 2). The decrease rate of SUV in each tumor after 3-BrPA administration ranged from 13.33 to 69.72 immediately after treatment and from 40.35 to 93.52 a week after treatment (Table 1).


FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.

Park HS, Chung JW, Jae HJ, Kim YI, Son KR, Lee MJ, Park JH, Kang WJ, Yoon JH, Chung H, Lee K - Korean J Radiol (2007 May-Jun)

Line graph shows the chronological SUV changes of the VX2 liver tumors in each animal. Seven animals showed a gradually decreased SUV, but the other three animals showed rising tendency of FDG uptake at one week after treatment. * Tx = treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2627418&req=5

Figure 2: Line graph shows the chronological SUV changes of the VX2 liver tumors in each animal. Seven animals showed a gradually decreased SUV, but the other three animals showed rising tendency of FDG uptake at one week after treatment. * Tx = treatment.
Mentions: The SUV was significantly decreased immediately after 3-BrPA administration (before treatment: 3.87 ±1.51 [mean ±SD], immediately after treatment: 2.05 ±1.21, p = 0.002, Wilcoxon signed rank test). On the one week follow up PET scan, the FDG uptake remained significantly lower than that before treatment (1.41 ±0.73, p = 0.002), and the SUV was persistently decreased in seven rabbits, but it showed a slightly increasing tendency in three rabbits (animals 1, 2 and 6) (Fig. 2). The decrease rate of SUV in each tumor after 3-BrPA administration ranged from 13.33 to 69.72 immediately after treatment and from 40.35 to 93.52 a week after treatment (Table 1).

Bottom Line: The SUV was significantly decreased immediately after 3-BrPA administration (2.05+/-1.21) (p = 0.002, Wilcoxon signed rank test).On the one-week follow up PET scan, the FDG uptake remained significantly lower (SUV 1.41+/-0.73) than that before treatment (p = 0.002), although three out of ten animals showed a slightly increasing tendency for the FDG uptake.There was no significant correlation between the SUV or the SUV decrease rate and the tumor necrosis rate in that range.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Seoul National University College of Medicine, Institute of Radiation Medicine, Seoul National University Medical Research Center and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea.

ABSTRACT

Objective: We wanted to investigate the feasibility of using FDG-PET for evaluating the antitumor effect of intraarterial administration of a hexokinase II inhibitor, 3-bromopyruvate (3-BrPA), in a rabbit VX2 liver tumor model.

Materials and methods: VX2 carcinoma was grown in the livers of ten rabbits. Two weeks later, liver CT was performed to confirm appropriate tumor growth for the experiment. After tumor volume-matched grouping of the rabbits, transcatheter intraarterial administration of 3-BrPA was performed (1 mM and 5 mM in five animals each, respectively). FDG-PET scan was performed the day before, immediately after and a week after 3-BrPA administration. FDG uptake was semiquantified by measuring the standardized uptake value (SUV). A week after treatment, the experimental animals were sacrificed and the necrosis rates of the tumors were calculated based on the histopathology.

Results: The SUV of the VX2 tumors before treatment (3.87+/-1.51 [mean+/-SD]) was significantly higher than that of nontumorous liver parenchyma (1.72+/-0.34) (p < 0.0001, Mann-Whitney U test). The SUV was significantly decreased immediately after 3-BrPA administration (2.05+/-1.21) (p = 0.002, Wilcoxon signed rank test). On the one-week follow up PET scan, the FDG uptake remained significantly lower (SUV 1.41+/-0.73) than that before treatment (p = 0.002), although three out of ten animals showed a slightly increasing tendency for the FDG uptake. The tumor necrosis rate ranged from 50.00% to 99.90% (85.48%+/-15.87). There was no significant correlation between the SUV or the SUV decrease rate and the tumor necrosis rate in that range.

Conclusion: Even though FDG-PET cannot exactly reflect the tumor necrosis rate, FDG-PET is a useful modality for the early assessment of the antitumor effect of intraarterial administration of 3-BrPA in VX2 liver tumor.

Show MeSH
Related in: MedlinePlus